Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Emyria.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Avita jumps 14pc on FDA approval; Emyria to start trial on landmark MDMA therapy
Health & Biotech
Weed Week: A ‘shroom boom’ could see psychedelics follow cannabis’ explosive footsteps
Health & Biotech
Could these Aussie psychedelics stocks carve a slice out of a ‘potential $63 billion’ global market?
News
CLOSING BELL: Nobody’s quite game to pick the bottom after the ASX makes it 5 losses on the trot
Health & Biotech
Weed Week: 420 reminds us that cannabis stocks may be down, but by no means out
News
Market Highlights: Solid start to the US earnings season, and 5 ASX small caps to watch on Tuesday
Health & Biotech
Weed Week: Most Aussies still use illicit cannabis, but more are now turning to prescriptions
Health & Biotech
ASX Health Stocks: Paradigm shows good Phase 2 results, Race Oncology jumps 8pc after third party report on Zantrene
Health & Biotech
WEED WEEK: Wellnex teams up with Chemist Warehouse for new cannabis products
News
Market Highlights: Last hike? Market hopeful the Fed will pause; and a crackdown on crypto influencers
Health & Biotech
ASX Health Stocks: Emyria partners with Pax Centre to provide psychedelics therapy for PTSD sufferers
Health & Biotech
As dementia takes toll on Aussies, here’s why Alterity and these ASX biotechs are in the box seat
Health & Biotech
ASX Health Stocks: Emyria surges another 10pc; cannabis play Vitura delivers record profit
Health & Biotech
Weed Week: Greens reckon legal cannabis could generate $28 billion over a decade
News
Rise and Shine: Everything you need to know before the ASX opens
News
CLOSING BELL: Not even the promise of top-shelf psychedelics could lift the market’s mood
News